Does tranexamic acid reduce blood transfusion cost for primary total hip arthroplasty? A case-control study.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 25534861.
- Also identified by DOI 10.1016/j.arth.2014.08.020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Peri-operative tranexamic acid (TXA) significantly reduces the need for allogeneic blood transfusion in total hip arthroplasty (THA) and thus hospital costs are reduced. Before employing TXA in primary THA at our institution, facility costs were $286.90/THA for blood transfusion and required 0.45 man-hours/THA (transfusion rate 19.87%). After incorporating TXA, the cost for intravenous application was $123.38/THA for blood transfusion and TXA medication and 0.07 man-hours/THA (transfusion rate 4.39%) and the cost for topical application was $132.41/THA for blood transfusion and TXA and 0.14 man-hours/THA (transfusion rate 12.86%). TXA has the potential to reduce the facility cost per THA and the man-hours/THA from blood transfusions.
Medical subject headings
- Antifibrinolytic Agents
- Arthroplasty, Replacement, Hip
- Blood Transfusion
- Tranexamic Acid
Anatomy
- hip